Short answer
Anteris Technologies Global Corp. (AVR) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $519,000 (up 21.0% year over year) with net income of −$27M.
Q3 2026 key financials · XBRL
- Revenue
- $519,000
- +21.0% YoY · −48.6% QoQ
- Net income
- −$27M
- −20.6% YoY · +7.8% QoQ
- Operating margin
- -5749.7%
- EPS (diluted)
- −$0.27
- +56.5% YoY · +10.0% QoQ
Source: XBRL data from the Anteris Technologies Global Corp. (AVR) Q3 2026 10-Q on SEC EDGAR. USD.
Anteris Technologies Global Corp. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $519K, up 21% YoY from $429K, driven by higher 4C tissue-product sales
- Gross margin percentage not disclosed, described as generally consistent YoY
- Operating loss $29.8M vs $22.3M YoY, operating margin -5,749% vs -5,189%
- Cash, equivalents and restricted cash $236.3M; operating cash outflow $72.4M for nine months
- Financing provided $298.4M, including $308.6M net stock proceeds; ongoing losses and additional funding needs expected
Risk Factors
- Regulatory risk: PARADIGM Trial approval under FDA IDE could be revoked
- Clinical risk: PARADIGM Trial may be unsuccessful despite FDA authorization
- Approval risk: DurAVR THV System may not receive FDA PMA
- Compliance risk: FDA may impose costly post-market testing or controls after PMA
- Revenue risk: approval delays could prevent revenue generation or profitability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Anteris Technologies Global Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.